Melevodopa, also known as levodopa methyl ester (LDME) and sold under the brand name Levomet, is a dopaminergic agent. It is the methyl ester of levodopa.[1] It is used in oral tablet form as an effervescent prodrug with 250 times the water solubility of tablet levodopa.[2][3] In combination with carbidopa, as melevodopa/carbidopa (brand name Sirio), it is approved for use in the treatment of Parkinson's disease.[4][5]

See also

References

  1. ^ Buckingham J, Baggaley K, Roberts A, Szabo L (2010). Dictionary of Alkaloids with CD-ROM. CRC Press. p. 103. ISBN 978-1-4200-7770-4. Retrieved 28 September 2024.
  2. ^ Hickey P, Stacy M (2011). "Available and emerging treatments for Parkinson's disease: a review". Drug Design, Development and Therapy. 5: 241–254. doi:10.2147/DDDT.S11836. PMC 3096539. PMID 21607020.
  3. ^ Stocchi F, Marconi S (July 2010). "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)". Clin Neuropharmacol. 33 (4): 198–203. doi:10.1097/WNF.0b013e3181de8924. PMID 20414107.
  4. ^ "Melevodopa/carbidopa". AdisInsight. Springer Nature Switzerland AG. 23 September 2021. Retrieved 27 September 2024.
  5. ^ "Melevodopa: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 April 2015. Retrieved 27 September 2024.



Allikas: https://en.wikipedia.org/wiki/Melevodopa
No tags for this post.